Karyopharm Therapeutics (KPTI) Key Ratios
$0.61
As on 08-Oct-2026 10:37EDT
Market cap
$18 Mln
Revenue (TTM)
$147 Mln
P/E Ratio
--
P/B Ratio
12
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -4.66 | -11.86 | 6.81 | 0.14 | 7.47 |
| EBIT | -447.66 | -107.35 | -123.46 | -20.35 | 0.81 |
| Net Profit | -199.32 | -79.92 | -81.88 | -25.55 | -1.67 |
| EPS | -155.64 | 46.41 | 13.37 | 8.84 | 10.20 |
| Book Value | -- | -- | -- | -- | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -70.35 | -69.35 | -120.04 | -102.79 | -26.81 |
| Net Margin
| -- | -81.36 | -153.28 | -- | -- |
| Return on equity
| 105.51 | 302.35 | -- | 81.86 | 47.43 |
| Return on Capital
| 106.96 | 20.77 | -- | 771.62 | -309.92 |
| Return on Assets
| -76.42 | -63.85 | -99.96 | -143.71 | -37.75 |
| Debt to Equity (x)
| -- | -- | -0.63 | -0.80 | -1.05 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
--
|
771.62
|
-309.92
|
-140.83
|
-125.54
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
--
--
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
--
|
81.86
|
47.43
|
187.23
|
343.18
|
|
Peer Median
|
-39.75
|
--
|
--
|
--
|
--
|
ROA
-99.96
Lower than Peers by 68.77
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
-99.96
|
-143.71
|
-37.75
|
-47.81
|
-49.83
|
|
Peer Median
|
-31.19
|
--
|
--
|
--
|
--
|
EBIT Margin
-120.04
Lower than Peers by 43.51
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
-120.04
|
-102.79
|
-26.81
|
-81.46
|
-89.08
|
|
Peer Median
|
-76.53
|
--
|
--
|
--
|
--
|
Net Margin
-153.28
Lower than Peers by 67.71
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
-153.28
|
-134.21
|
-52.62
|
-97.99
|
-103.73
|
|
Peer Median
|
-85.56
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
Lower than Peers by 0.00
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.00
|
--
|
--
|
--
|
--
|
Revenue Growth
6.81
Lower than Peers by 47.81
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
6.81
|
0.01
|
-0.01
|
-0.07
|
-0.25
|
|
Peer Median
|
54.63
|
--
|
--
|
--
|
--
|
EBIT Growth
-123.46
Lower than Peers by 122.08
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
-123.46
|
-285.56
|
67.26
|
14.99
|
-43.11
|
|
Peer Median
|
-1.39
|
--
|
--
|
--
|
--
|
Net Profit Growth
-81.88
Lower than Peers by 75.08
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
-81.88
|
-156.52
|
46.60
|
13.43
|
-33.20
|
|
Peer Median
|
-6.80
|
--
|
--
|
--
|
--
|
EPS Growth
13.37
Lower than Peers by 0.76
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
13.37
|
-0.18
|
0.51
|
0.32
|
-0.29
|
|
Peer Median
|
14.14
|
--
|
--
|
--
|
--
|
Book Value Growth
58.84
Higher than Peers by 68.33
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
58.84
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-9.50
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
-0.63
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
-0.63
|
-0.80
|
-1.05
|
-1.30
|
-10.75
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.00
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
0.00
|
-0.08
|
-0.13
|
-0.02
|
-0.17
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
0.79
Lower than Peers by 5.04
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
0.79
|
1.12
|
1.70
|
3.37
|
5.31
|
|
Peer Median
|
5.84
|
--
|
--
|
--
|
--
|
Quick Ratio
0.76
Lower than Peers by 4.94
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
0.76
|
1.08
|
1.64
|
3.32
|
5.25
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
-3.56
Lower than Peers by 1.41
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
-3.56
|
-3.27
|
-1.04
|
-4.99
|
-5.60
|
|
Peer Median
|
-2.15
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
20.37
Higher than Peers by 1.32
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
20.37
|
17.92
|
21.18
|
18.46
|
29.98
|
|
Peer Median
|
19.05
|
--
|
--
|
--
|
--
|
Asset Turnover
0.65
Higher than Peers by 0.59
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
0.65
|
1.07
|
0.72
|
0.49
|
0.47
|
|
Peer Median
|
0.07
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
--
|
71.20
|
72.59
|
92.60
|
80.90
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
--
|
269.44
|
236.59
|
268.54
|
291.82
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
--
|
279.66
|
250.21
|
217.88
|
153.30
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
--
|
60.97
|
58.97
|
143.27
|
219.42
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
--
|
-0.68
|
-0.07
|
-0.05
|
-0.12
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
12.05
Higher than Peers by 7.57
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
12.05
|
-0.46
|
-0.03
|
-0.05
|
-1.22
|
|
Peer Median
|
4.48
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-1.85
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
-1.85
|
-2.03
|
-2.37
|
0.07
|
0.56
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
18
Lower than Peers by 123
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Karyopharm Therapeutics (KPTI)
|
18
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|